Literature DB >> 11075776

Injectional anthrax in a heroin skin-popper.

S H Ringertz, E A Høiby, M Jensenius, J Maehlen, D A Caugant, A Myklebust, K Fossum.   

Abstract

Anthrax is rare in western Europe but may arise sporadically in people exposed to animal products from endemic areas. A heroin-injecting drug user presented with a severe soft-tissue infection at the injection site, septic shock, and meningitis. A gram-positive endospore-forming aerobic rod was isolated from the soft tissue and cerebrospinal fluid; confirmation of Bacillus anthracis was made by PCR. Since contaminated heroin was the probable source of infection, this case is of concern and warrants surveillance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11075776     DOI: 10.1016/s0140-6736(00)03133-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

2.  Improved Discrimination of Bacillus anthracis from Closely Related Species in the Bacillus cereus Sensu Lato Group Based on Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.

Authors:  Viktoria I Pauker; Bryan R Thoma; Gregor Grass; Pauline Bleichert; Matthias Hanczaruk; Lothar Zöller; Sabine Zange
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 3.  Antimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature Review.

Authors:  Satish K Pillai; Eileen Huang; Julie T Guarnizo; Jamechia D Hoyle; Stefan Katharios-Lanwermeyer; Theresa K Turski; William A Bower; Katherine A Hendricks; Dana Meaney-Delman
Journal:  Health Secur       Date:  2015-12-01

Review 4.  Anthrax infection.

Authors:  Daniel A Sweeney; Caitlin W Hicks; Xizhong Cui; Yan Li; Peter Q Eichacker
Journal:  Am J Respir Crit Care Med       Date:  2011-08-18       Impact factor: 21.405

5.  Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.

Authors:  C K Cote; L Kaatz; J Reinhardt; J Bozue; S A Tobery; A D Bassett; P Sanz; S C Darnell; F Alem; A D O'Brien; S L Welkos
Journal:  J Med Microbiol       Date:  2012-07-05       Impact factor: 2.472

Review 6.  An overview of anthrax infection including the recently identified form of disease in injection drug users.

Authors:  Caitlin W Hicks; Daniel A Sweeney; Xizhong Cui; Yan Li; Peter Q Eichacker
Journal:  Intensive Care Med       Date:  2012-04-24       Impact factor: 17.440

7.  Epidemiological findings and medical, legal, and public health challenges of an investigation of severe soft tissue infections and deaths among injecting drug users -- Ireland, 2000.

Authors:  K Murray-Lillibridge; J Barry; S Reagan; D O'flanagan; G Sayers; C Bergin; E Keenan; S O'briain; P Plunkett; G McMahon; C Keane; P O'sullivan; D Igoe; L Mullen; M Ward; A Smith; M Fischer
Journal:  Epidemiol Infect       Date:  2005-11-29       Impact factor: 2.451

8.  Severe systemic Bacillus anthracis infection in an intravenous drug user.

Authors:  Jessica Veitch; Anoushka Kansara; Daniel Bailey; Ildiko Kustos
Journal:  BMJ Case Rep       Date:  2014-02-13

9.  The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax.

Authors:  Wun-Ju Shieh; Jeannette Guarner; Christopher Paddock; Patricia Greer; Kathleen Tatti; Marc Fischer; Marci Layton; Michael Philips; Eddy Bresnitz; Conrad P Quinn; Tanja Popovic; Bradley A Perkins; Sherif R Zaki
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  Multilocus sequence typing scheme for bacteria of the Bacillus cereus group.

Authors:  Erlendur Helgason; Nicolas J Tourasse; Roger Meisal; Dominique A Caugant; Anne-Brit Kolstø
Journal:  Appl Environ Microbiol       Date:  2004-01       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.